Originally doing business as Matrix Biosciences, then as Protein Delivery and finally as Nobex Corporation, in March 2006, after having filed for bankruptcy in Jan 2006, the firm's remaining assets were acquired by India-based Biocon Ltd. Nobex Corporation, a drug development company, had been developing oral peptide therapeutics offering Oratonin, an oral modified salmon calcitonin with antibone-resorptive and analgesic properties for bone disorders; APAZA compound, an oral tablet for inflammatory bowel disease; and insulin in an oral tablet for diabetes. Focused on modifying drug molecules to improve medications for chronic diseases, derived from the Latin word "Obex", the Nobex name signifies "No Barriers", the new name to spoke to the firm's willingness to overcome the challenges of drug delivery. Specializing in applying medicinal chemistry to therapeutic drug delivery, the Nobex focus was on enabling the oral delivery of protein, peptide and small molecule drugs at the time available only through injection.
